BiotechTube
ALKemist Bio

ALKemist Bio

Milan, Italy· Est.
alkemistbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

ALKemist Bio is a private, preclinical-stage biotech company founded in 2018 and based in Milan, Italy. It is pioneering a novel, dual-platform approach to cell therapy, developing both CAR-T and TCR-T treatments specifically engineered to target the ALK oncogene across various solid tumors, including neuroblastoma and NSCLC. The company is built on foundational research from Professor Roberto Chiarle and is backed by a €6.9M investment round, positioning it to address a significant unmet need in oncology for patients with ALK-driven cancers resistant to standard therapies.

Oncology

Technology Platform

Dual-platform autologous T cell therapy: CAR-T for surface ALK expression and TCR-T for intracellular ALK peptides presented by MHC/HLA.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The significant unmet need in ALK-positive cancers, particularly after TKI resistance develops, creates a large addressable market.
The company's dual-platform approach allows it to target both pediatric (neuroblastoma) and major adult (NSCLC) oncology markets, and its therapies have potential for synergy with existing TKIs and checkpoint inhibitors.

Risk Factors

Major risks include the technical challenges of applying cell therapy to solid tumors (trafficking, persistence, toxicity), the high burn rate and need for substantial future financing, and competition from next-generation TKIs and other modalities from larger, better-resourced companies.

Competitive Landscape

Competition includes established ALK tyrosine kinase inhibitors (e.g., from Pfizer, Roche, Takeda) and developers of next-generation TKIs. In cell therapy, the solid tumor space is crowded but few are specifically targeting ALK, giving ALKemist Bio a focused niche. However, larger biopharma companies with cell therapy platforms could enter the space.

More companies in Cell & Gene Therapy →More companies in Italy →